Free shipping on all orders over $ 500

Merimepodib

Cat. No. M9758
Merimepodib Structure
Synonym:

VX-497

Size Price Availability
10mg USD 180  USD200 4-7 Days
25mg USD 405  USD450 4-7 Days
50mg USD 585  USD650 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Merimepodib, also known as VX-497, is an orally bioavailable IMPDH inhibitor with broad spectrum antiviral activities. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. 

In vivo, oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED(50) value of approximately 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 452.46
Formula C23H24N4O6
CAS Number 198821-22-6
Purity >99%
Solubility DMSO ≥ 27 mg/mL
Storage at -20°C
References

The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice
C J Decker, et al. Dvrgs Exp Clin Res. 2001;27(3):89-95. PMID: 11447770.

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent
J Jain, et al. J Pharm Sci. 2001 May;90(5):625-37. PMID: 11288107.

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
W Markland, et al. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. PMID: 10722482.

Related HCV Protease Products
Inarigivir soproxil

Inarigivir soproxil, also known as SB 9200, is a novel agonist of innate immunity, which shows potent antiviral activity against resistant HCV variants.

Ombitasvir

Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366 pM against genotype 6a.

Paritaprevir

Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 values of 1 and 0.21 nM for HCV 1a and 1b, respectively.

BLT-1

Block lipid transport-1 (BLT-1) is a specific inhibitor of the SR-BI (Scavenger receptor, class B, type I) mediated lipid transfer.

Velpatasvir

Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Merimepodib, VX-497 supplier, HCV Protease, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.